Trovagene is a clinical-stage, oncology therapeutics company, taking a precision medicine approach and integrating a biomarker strategy to develop targeted drugs to treat leukemias, lymphomas and solid tumor cancers. Our drug candidate, onvansertib, is a first-in-class, 3rd generation Polo-like Kinase Inhibitor with best-in-class attributes. Onvansertib is highly-selective for PLK1, which is over-expressed in most cancers; it is orally administered; synergistic in combination with numerous chemotherapies and targeted therapeutics; has a half-life of 24-hours which allows for flexibility in dosing and schedule. We are developing onvansertib as part of combination regimens with already approved drugs for the treatment of cancers and indications where there is a significant medical need for new treatment options. Source
No articles found.
We exist to create an alternate future for people living with neurodegenerative di...
We exist to create an alternate future for peop...
Agile Therapeutics is a forward-thinking women's healthcare company dedicated to f...
Agile Therapeutics is a forward-thinking women'...
ProPhase Labs is a diversified medical science and technology company. We develop,...
ProPhase Labs is a diversified medical science ...
We are a pharmaceutical company currently in the preclinical stage, dedicated to d...
We are a pharmaceutical company currently in th...
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on...
Deciphera Pharmaceuticals is a clinical-stage b...
Ascendis Pharma is applying its innovative technology platform to build a leading,...
Ascendis Pharma is applying its innovative tech...
Castle Biosciences is a skin cancer diagnostics company focused on providing physi...
Castle Biosciences is a skin cancer diagnostics...
Join the National Investor Network and get the latest information with your interests in mind.